A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT

Exclusion Criteria

• •1. BMT program will initiate referral, utilizing Form: 170102, Radiation Oncology Consultation.
• •2. Patients undergo pre-transplant testing, as defined in BMT SOPs:CLNAL002: Related (MRD, Haplo) Allogeneic Recipient Evaluation and Management or CLNAL011: Unrelated (MUD, MMUD, CBU) Allogeneic Recipient Evaluation and Management, per below.
• •i. BMT SOP's include baseline pulmonary function tests (PFTs). Patient with decreased FVC, FEV1 and or DLCO (adjusted for hemoglobin) or pulmonary history will have pulmonary consult, at the discretion of the BMT physician prior to undergoing myeloablative radiation.
• •ii. Medical history and physical by BMT provider.
• •iii. The following laboratory tests (additional testing may be required for positive results):
• •ABO group and Rh type
• •Red Blood Cell Antibody Screen.
• •HLA typing and confirmatory typing
• •HLA antibody screen, class I and II, performed within 30 days of transplant.
• •Complete blood count (CBC) with differential.
• •Basic metabolic panel, including glucose and to include at a minimum electrolyte evaluation of potassium, calcium, magnesium, and phosphorus.
• •Blood urea nitrogen (BUN)
• •Creatinine
• •Liver Function Tests including: Total bilirubin, Alkaline phosphatase, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Lactate dehydrogenase (LDH), Albumin, Total Protein, Urinalysis
• •1. Patient receiving less than 1200 cGy of TBI
• •2. Previous history of thoracic radiation therapy including previous TBI
• •3. All premenopausal women will require a urine qualitative pregnancy test to exclude pregnancy. Pregnant women will be excluded from the study.
• •4. Prisoners
• •5. Patient not meeting transplant criteria per BMT physician.